104 related articles for article (PubMed ID: 11384804)
1. The role of tamoxifen in the treatment of symptomatic uterine leiomyomata -- a pilot study.
Sadan O; Ginath S; Sofer D; Rotmensch S; Debby A; Glezerman M; Zakut H
Eur J Obstet Gynecol Reprod Biol; 2001 Jun; 96(2):183-6. PubMed ID: 11384804
[TBL] [Abstract][Full Text] [Related]
2. Mitotically active leiomyoma of the uterus in a postmenopausal breast cancer patient receiving tamoxifen.
Liu IF; Yen YS; Cheng YM; Chou CY
Taiwan J Obstet Gynecol; 2006 Jun; 45(2):167-9. PubMed ID: 17197361
[TBL] [Abstract][Full Text] [Related]
3. Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy.
Wilkens J; Chwalisz K; Han C; Walker J; Cameron IT; Ingamells S; Lawrence AC; Lumsden MA; Hapangama D; Williams AR; Critchley HO
J Clin Endocrinol Metab; 2008 Dec; 93(12):4664-71. PubMed ID: 18765509
[TBL] [Abstract][Full Text] [Related]
4. A clinical trial of the effects of tibolone administered with gonadotropin-releasing hormone analogues for the treatment of uterine leiomyomata.
Palomba S; Affinito P; Tommaselli GA; Nappi C
Fertil Steril; 1998 Jul; 70(1):111-8. PubMed ID: 9660431
[TBL] [Abstract][Full Text] [Related]
5. Co-occurrence of atypical endometriosis, subserous uterine leiomyomata, sactosalpinx, serous cystadenoma and bilateral hemorrhagic corpora lutea in a perimenopausal adipose patient taking tamoxifen (20 mg/day) for invasive lobular breast cancer.
Ebert AD; Rosenow G; David M; Mechsner S; Magalov IS; Papadopoulos T
Gynecol Obstet Invest; 2008; 66(3):209-13. PubMed ID: 18645252
[TBL] [Abstract][Full Text] [Related]
6. Regression of tamoxifen-stimulated massive uterine fibroid after conversion to anastrozole.
Attilakos G; Fox R
J Obstet Gynaecol; 2005 Aug; 25(6):609-10. PubMed ID: 16234156
[No Abstract] [Full Text] [Related]
7. Goserelin acetate 10.8 mg plus iron versus iron monotherapy prior to surgery in premenopausal women with iron-deficiency anemia due to uterine leiomyomas: results from a Phase III, randomized, multicenter, double-blind, controlled trial.
Muneyyirci-Delale O; Richard-Davis G; Morris T; Armstrong J
Clin Ther; 2007 Aug; 29(8):1682-91. PubMed ID: 17919549
[TBL] [Abstract][Full Text] [Related]
8. Use of transvaginal ultrasonography to monitor the effects of tamoxifen on uterine leiomyoma size and ovarian cyst formation.
Schwartz LB; Rutkowski N; Horan C; Nachtigall LE; Snyder J; Goldstein SR
J Ultrasound Med; 1998 Nov; 17(11):699-703. PubMed ID: 9805306
[TBL] [Abstract][Full Text] [Related]
9. Endometrial thickness and ovarian cysts as measured by ultrasound in asymptomatic postmenopausal breast cancer patients on various adjuvant treatments including tamoxifen.
Lindahl B; Andolf E; Ingvar C; Liedman R; Ranstam J; Willén R
Anticancer Res; 1997; 17(5B):3821-4. PubMed ID: 9427787
[TBL] [Abstract][Full Text] [Related]
10. The effect of anastrazole on symptomatic uterine leiomyomata.
Varelas FK; Papanicolaou AN; Vavatsi-Christaki N; Makedos GA; Vlassis GD
Obstet Gynecol; 2007 Sep; 110(3):643-9. PubMed ID: 17766612
[TBL] [Abstract][Full Text] [Related]
11. A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata.
Chwalisz K; Larsen L; Mattia-Goldberg C; Edmonds A; Elger W; Winkel CA
Fertil Steril; 2007 Jun; 87(6):1399-412. PubMed ID: 17307170
[TBL] [Abstract][Full Text] [Related]
12. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids.
Lethaby A; Vollenhoven B; Sowter M
Cochrane Database Syst Rev; 2001; (2):CD000547. PubMed ID: 11405968
[TBL] [Abstract][Full Text] [Related]
13. The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata.
Williams AR; Critchley HO; Osei J; Ingamells S; Cameron IT; Han C; Chwalisz K
Hum Reprod; 2007 Jun; 22(6):1696-704. PubMed ID: 17339234
[TBL] [Abstract][Full Text] [Related]
14. Prolapsed leiomyoma with severe haemorrhage after GnRH analogue therapy.
Kriplani A; Agarwal N; Parul D; Bhatla N; Saxena AK
J Obstet Gynaecol; 2002 Jul; 22(4):449-51. PubMed ID: 12521484
[No Abstract] [Full Text] [Related]
15. Abnormalities detected on transvaginal ultrasonography in tamoxifen-treated postmenopausal breast cancer patients may represent endometrial cystic atrophy.
McGonigle KF; Shaw SL; Vasilev SA; Odom-Maryon T; Roy S; Simpson JF
Am J Obstet Gynecol; 1998 Jun; 178(6):1145-50. PubMed ID: 9662294
[TBL] [Abstract][Full Text] [Related]
16. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids.
Lethaby A; Vollenhoven B; Sowter M
Cochrane Database Syst Rev; 2000; (2):CD000547. PubMed ID: 10796723
[TBL] [Abstract][Full Text] [Related]
17. Anastrozole versus tamoxifen treatment in postmenopausal women with endocrine-responsive breast cancer and tamoxifen-induced endometrial pathology.
Gerber B; Krause A; Reimer T; Mylonas I; Makovitzky J; Kundt G; Janni W
Clin Cancer Res; 2006 Feb; 12(4):1245-50. PubMed ID: 16489080
[TBL] [Abstract][Full Text] [Related]
18. [Uterine abnormalities in non menopausal women who received tamoxifen for breast cancer adjuvant therapy].
d'Arailh AS; Michy T; Pioud R; Dravet F; Classe JM
Gynecol Obstet Fertil; 2007 Dec; 35(12):1215-9. PubMed ID: 18035581
[TBL] [Abstract][Full Text] [Related]
19. Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo.
Barlow DH; Lumsden MA; Fauser BC; Terrill P; Bestel E
Hum Reprod; 2014 Mar; 29(3):480-9. PubMed ID: 24457604
[TBL] [Abstract][Full Text] [Related]
20. [Role of medical treatment for symptomatic leiomyoma management in premenopausal women].
Koskas M; Chabbert-Buffet N; Douvier S; Huchon C; Paganelli E; Derrien J
J Gynecol Obstet Biol Reprod (Paris); 2011 Dec; 40(8):858-74. PubMed ID: 22071015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
